HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IRMD
IRadimed Corporation
IRMD's fundamentals are strong: it turned 29% of its revenue into free cash flow and free cash flow grew 77%. At 46x earnings, it's trading above its usual 41x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IRMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
IRMD's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 32x | $59.44 | -30% |
| Forward | 36x | $85.23 | — |
| Fair | 41x | $76.32 | -10% |
| Current | 46x | $85.23 | — |
| Expensive | 71x | $133 | +57% |
Historical ranges are pointers, not guarantees.
IRMD's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 36x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IRMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
IRMD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +28% |
| Q3 2026 | $1.87 | +13% |
| Q2 2026 | $1.79 | +10% |
| Q1 2026 | $1.83 | +18% |
| Q4 2025 | $1.75 | +17% |
| Q3 2025 | $1.65 | +14% |
| Q2 2025 | $1.62 | +12% |
| Q1 2025 | $1.55 | +11% |
| Q4 2024 | $1.50 | +11% |
IRMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IRMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2M | +14% |
| Q2 2026 | $20.5M | +0.3% |
| Q1 2026 | $22M | +13% |
| Q4 2025 | $22.7M | +17% |
| Q3 2025 | $21.2M | +16% |
| Q2 2025 | $20.4M | +14% |
| Q1 2025 | $19.5M | +11% |
| Q4 2024 | $19.4M | +11% |
IRMD's revenue has grown year over year for 23 quarters in a row: $24M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +1.4 points |
| Q2 2026 | 31% | -2 points |
| Q1 2026 | 33% | +5.1 points |
| Q4 2025 | 31% | +1.4 points |
| Q3 2025 | 32% | +0.6 points |
| Q2 2025 | 33% | +1.9 points |
| Q1 2025 | 28% | +0.9 points |
| Q4 2024 | 30% | +0.3 points |
IRMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IRMD on cash flow, with more consistent year-over-year improvement.
IRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +17% |
| Q2 2026 | $5.8M | +13% |
| Q1 2026 | $7.9M | +1226% |
| Q4 2025 | $5.6M | +76% |
| Q3 2025 | $5.8M | +10% |
| Q2 2025 | $5.1M | -7.2% |
| Q1 2025 | $594.6K | -84% |
| Q4 2024 | $3.2M | -5.4% |
IRMD generated $26M in free cash flow over the past year, up 77% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +4K shares |
| 1 year | +0.1% | +15.9K shares |
| 3 years | +1.1% | +140K shares |
| 5 years | +2.2% | +272K shares |
| Available history | +4.9% | +600K shares |
IRMD has 13M diluted shares, about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.2x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
IRMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 36.0 | Neutral |
IRMD's weekly RSI is 47 (neutral) and its Stochastic is 36 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IRMD PE vs Healthcare Sector
| Metric | IRMD | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 76% above |
| PE % | 60 | 29 | 31 pts above |
IRMD is trading at 46x earnings, a 76% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.1 | 0.1% above |
| 20 week MA | $88.2 | 3.3% below |
| 50 week MA | $92.6 | 8% below |
| 100 week MA | $77.7 | 9.7% above |
| 200 week MA | $61.2 | 39% above |
IRMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.6 | $23.3 | -5.3% |
| 2021 | $23.3 | $45.9 | +97% |
| 2022 | $45.9 | $28.0 | -39% |
| 2023 | $28.0 | $47.5 | +70% |
| 2024 | $47.5 | $54.7 | +15% |
| 2025 | $54.7 | $97.5 | +78% |
| 2026 YTD | $97.5 | $85.2 | -13% |
IRMD has the edge over HIMS on returns for 2026, with the stronger performance.